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hondrogenesis is a multistep process culminating
in the establishment of a precisely patterned template
for bone formation. Previously, we identiﬁed a loss
in retinoid receptor–mediated signaling as being necessary
and sufﬁcient for expression of the chondroblast pheno-
type (Weston et al., 2000. 
 
J. Cell Biol.
 
 148:679–690).
 
Here we demonstrate a close association between retinoic
acid receptor (RAR) activity and the transcriptional activity
of Sox9, a transcription factor required for cartilage for-
mation. Speciﬁcally, inhibition of RAR-mediated signaling
in primary cultures of mouse limb mesenchyme results in
increased Sox9 expression and activity. This induction is
attenuated by the histone deacetylase inhibitor, trichostatin
A, and by coexpression of a dominant negative nuclear
receptor corepressor-1, indicating an unexpected require-
C
 
ment for RAR-mediated repression in skeletal progenitor
differentiation.
Inhibition of RAR activity results in activation of the p38
mitogen-activated protein kinase (MAPK) and protein kinase
A (PKA) pathways, indicating their potential role in the
regulation of chondrogenesis by RAR repression. Accordingly,
activation of RAR signaling, which attenuates differentiation,
can be rescued by activation of p38 MAPK or PKA. In
summary, these ﬁndings demonstrate a novel role for active
RAR-mediated gene repression in chondrogenesis and
establish a hierarchical network whereby RAR-mediated
signaling functions upstream of the p38 MAPK and PKA
signaling pathways to regulate emergence of the chondro-
blast phenotype.
 
Introduction
 
Almost all skeletal elements form on a cartilage template that is
established early during embryogenesis to provide a precisely
patterned framework for the future skeleton. During chon-
drogenesis, numerous factors act together to coordinate
commitment and differentiation of skeletal progenitors such
that these processes occur in a spatial- and temporal-specific
manner. Of these factors, the retinoids have been known for
decades to have a considerable influence on cartilage formation.
Specifically, an imbalance in vitamin A metabolites, such as
retinoic acid (RA),* during development will result in severe
skeletal defects among a multitude of other developmental
anomalies (Hale, 1935; Warkany and Schraffenberger,
1946; Cohlan, 1953; Wilson et al., 1953; Kalter and Warkany,
1961). Modulation of RA availability during the time period
of chondrogenesis has the most profound impact on the
skeleton, suggesting that this period of skeletal development
is particularly sensitive to the retinoids (Kochhar, 1973;
Kwasigroch and Kochhar, 1980). Accordingly, retinoids have
been shown by several groups to inhibit chondrogenesis in vivo
and in vitro (for review see Underhill and Weston, 1998).
Of the intracellular retinoid binding proteins, nuclear
receptors are thought to mediate most of RA’s effects on cell
behavior. Two subfamilies of nuclear retinoid receptors exist:
the RA receptors (RARs) and the retinoid X receptors
(RXRs). Within each subfamily there are three subtypes (
 
 
 
,
 
 
 
, and 
 
 
 
), with multiple isoforms of each. These receptors
belong to the nuclear hormone receptor superfamily and
provide a level at which much of the diversity of retinoid
responses is generated (for review see Leid et al., 1992).
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Although ligand binding to the RARs followed by recruit-
ment of transcriptional coactivators is the basic mechanism
underlying RAR-mediated gene transcription, unliganded re-
ceptors are now recognized as having an equally important
function by actively repressing target gene expression through
the recruitment of nuclear corepressors and associated his-
tone deacetylases (Horlein et al., 1995; Chen et al., 1996;
Heinzel et al., 1997; Nagy et al., 1997; Koide et al., 2001).
The RARs and their isoforms exhibit dynamic expression
patterns throughout development (Mollard et al., 2000).
With respect to skeletal development in the limb, RAR
 
 
 
 is
expressed throughout the limb mesenchyme early in limb
development. As cells begin to differentiate into chondro-
cytes, RAR
 
 
 
 is downregulated, remaining highly expressed
in the perichondrium and in the interdigital region, whereas
RAR
 
 
 
 expression becomes localized to the cartilaginous ele-
ments (Dolle et al., 1989; Mendelsohn et al., 1991; Cash et
al., 1997; Mollard et al., 2000). Throughout limb morpho-
genesis, RAR
 
 
 
 is expressed in noncartilage-forming regions
such as the interdigital region (Mendelsohn et al., 1991).
We demonstrated previously that the continued expression
of RAR
 
 
 
 in prechondrogenic cells prevents their differentia-
tion, resulting in severely malformed skeletal elements in
transgenic mice (Cash et al., 1997; Weston et al., 2000).
Moreover, inhibition of RAR
 
 
 
 activity was sufficient to in-
duce chondrogenesis (Weston et al., 2000).
The proper size and shape of the developing skeletal ele-
ments relies on the appropriate control of chondroblast dif-
ferentiation. To date, the Sox genes, L-5, -6, and -9 are the
only known transcription factors through which this control
is achieved. These genes contain a high mobility group do-
main and belong to the Sox family of proteins that are ho-
mologous to the protein encoded by 
 
Sry
 
 (sex-determining
region of Y chromosome). Of this group, Sox9 is known to
play an essential role in establishing the precartilaginous
condensations and in initiating chondroblast differentiation
(Bi et al., 1999; Smits et al., 2001). Specifically, Sox9 binds
to a region within the first intron of the 
 
type II
 
 collagen gene
(
 
Col2a1
 
) to regulate its transcription (Lefebvre et al., 1996).
Mutations in 
 
Sox9
 
 underlie the rare congenital dwarfism
syndrome, campomelic dysplasia (Foster et al., 1994; Wag-
ner et al., 1994), and Sox9-null mice are embryonic lethal,
whereas 
 
Sox9
 
 
 
/
 
 
 
 cells in chimeric embryos are excluded
from all cartilages (Bi et al., 1999). Conversely, if ectopically
expressed, Sox9 will induce ectopic 
 
Col2a1
 
 expression and
cartilage formation (Bell et al., 1997; Healy et al., 1999).
Thus, Sox9 activation of 
 
Col2a1
 
 can be considered to be a
hallmark event in cartilage formation.
To date, only a handful of factors have been found to in-
fluence Sox9 expression and/or activity, all of which are
known modulators of chondrogenesis (Healy et al., 1999;
Murakami et al., 2000a,b). Here we demonstrate that Sox9
expression is regulated by the retinoid signaling pathway.
Our findings indicate that RAR-mediated repression is re-
quired for induction of Sox9
 
.
 
 Moreover, expression of a
dominant negative RAR leads to an increase in Sox9 re-
porter activity that is substantially greater than that elicited
by any other factor described thus far. In addition, we show
that the p38 MAPK and protein kinase A (PKA) signaling
cascades are required downstream of retinoid signaling for
 
chondroblast differentiation. Earlier studies have implicated
both p38 MAPK and PKA in chondrogenesis (Lee and
Chuong, 1997; Nakamura et al., 1999; Huang et al., 2000;
Oh et al., 2000; Yoon et al., 2000); however, for the first
time our results have enabled us to begin constructing a
model for the hierarchical network of events that direct
chondroblast differentiation.
 
Results
 
Inhibition of RAR activity enhances chondrogenesis 
through a Sox9-dependent mechanism
 
Previously, the continued expression of RAR
 
 
 
 activity in
transgenic mice was found to inhibit the chondropro-
genitor-to-chondroblast transition. Likewise, inhibition of
RAR
 
 
 
 using the subtype-specific antagonist, AGN194301,
induced differentiation in primary limb mesenchymal cul-
tures earlier than normal, resulting in a substantial increase
in the number of cartilage nodules that form in these cul-
tures. This induction of cartilage formation was confirmed
by the AGN194301-induced increase in expression of carti-
lage-specific genes such as 
 
Col2a1
 
 (Weston et al., 2000).
Given that Sox9 has been shown previously to be important
in regulating the expression of 
 
Col2a1
 
, we analyzed the ef-
fects of RAR
 
 
 
 antagonism on 
 
Sox9
 
 expression and activity
in an attempt to further understand the mechanism whereby
retinoid signaling regulates chondroblast differentiation.
To follow endogenous Sox9 activity in primary mesen-
chymal cells, a reporter-based approach was used in which
cells were transiently transfected with pGL3(4X48), a re-
porter containing four repeats of a Sox9 binding site from
the first intron of 
 
Col2a1.
 
 The RAR
 
 
 
-specific antagonist,
AGN194301 (301), induced a concentration-dependent
increase in reporter activity, whereas at-RA and the RAR
 
 
 
-
specific agonist, AGN193836 (836), attenuated reporter
activity (Fig. 1 A). Interestingly, when cells were treated
with the RAR pan-antagonist, AGN194310 (310), con-
centrations as low as 10 nM induced Sox9 reporter activity
greater than the maximal response elicited by higher doses
of 301. The maximal response to the pan antagonist was
 
 
 
530% induction at 50 nM, whereas the greatest induc-
tion of Sox9 reporter activity by the RAR
 
 
 
-specific antago-
nist was 
 
 
 
280% at 1 
 
 
 
M, a concentration at which this
antagonist affects ligand binding to other RAR subtypes
(Weston et al., 2000). Similar to RAR antagonism, the re-
duction in reporter activity caused by a pan-agonist such as
at-RA was more pronounced than that induced by the
RAR
 
 
 
-specific agonist, 836. at-RA reduces reporter activ-
ity to 53% at 5 nM, whereas in response to a much higher
dose of 836 (1 
 
 
 
M) reporter activity is reduced only to
64% of control. Together, these results indicate that a loss
in activity of at least two or more RARs is more efficient at
inducing cartilage differentiation than inhibition of the
RAR
 
 
 
 subtype alone.
Interestingly, the effects of RAR modulation on Sox9 ac-
tivity are opposite to that of the effects of each compound
on activity of a retinoic acid responsive reporter (pW1-
 
 
 
RARE
 
3
 
-Luc) in primary limb mesenchymal cells (Fig. 1 B).
For instance, at-RA activates the RARE reporter to a greater
extent than 836, whereas reporter activity is attenuated by 
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310 more effectively than by 301. Thus, activation of the
Sox9-responsive region of 
 
Col2a1
 
 appears to be very closely
associated with the status of RAR activity. This close associa-
tion is reflected in the response of primary cultures to treat-
ment with each compound (Fig. 1 C). Treatment with ei-
ther at-RA, the RAR
 
 
 
 agonist, or with the antagonists for 4 d
affects the formation of cartilage nodules in a manner that
would be predicted from their effects on Sox9 reporter activ-
ity. More specifically, at-RA is a more potent inhibitor of
cartilage nodule formation than 836, whereas the increase in
nodule formation can be observed at a lower concentration
of the pan-antagonist, (10 nM 310) compared with the
RAR
 
 
 
-specific antagonist (1 
 
 
 
M 301). Together, these re-
sults further validate the utility of the Sox9 reporter assay to
indirectly measure the status of chondroblast differentiation,
and more importantly they highlight the significant role of
RAR-mediated signaling in regulating expression of the
chondroblast phenotype.
The enhanced Sox9 reporter activity caused by RAR inhi-
bition is due, in part, to an increase in the expression of 
 
Sox9
 
mRNA, since treatment of primary cultures with 1 
 
 
 
M 301
results in an precocious increase in 
 
Sox9
 
 expression (Fig. 1
D). There is a noticeable increase in 
 
Sox9
 
 mRNA from 2-d
cultures treated with 301, but this increase over control cul-
tures is much less pronounced by days 4 and 6. Thus, inhi-
bition of RAR activity appears to induce an early transient
upregulation of 
 
Sox9
 
 mRNA that presumably contributes to
the enhanced Sox9 reporter activity seen in response to the
same compound.
To confirm the influence of RAR activity on chondroblast
differentiation, we introduced modified versions of the
RARs or RXRs into primary limb mesenchymal cultures to
 
follow their effect on Sox9 reporter activity. To examine the
effect of RAR activation without agonist addition, constitu-
tively active versions of RAR
 
 
 
 and RXR
 
 
 
 were used by fus-
ing the acidic activation domain of VP16 to the COOH ter-
minus of RAR and RXR referred to as RAR
 
 
 
VP16 and
RXR
 
 
 
VP16, respectively (Underhill et al., 1994). Here
we confirmed the ability of these modified receptors to po-
tently activate an RARE reporter in the absence of an ex-
ogenous agonist, since cotransfection of RAR
 
 
 
VP16 and
RXR
 
 
 
VP16 induced RARE reporter activity by 15- and 17-
fold, respectively, in the absence of agonist (Fig. 2 A).
In addition to modifying RARE activity with constitu-
tively active versions of the retinoid receptors, dominant
negative versions of the receptors (dnRAR
 
 
 
 and dnRXR
 
 
 
)
were also generated and transfected into primary limb mes-
enchymal cultures. These dominant negative derivatives
are COOH-terminal truncations of RAR
 
 
 
 and RXR
 
 
 
 that
retain their ability to bind DNA and ligand but lack the
AF-2 transactivation function (Damm et al., 1993; Feng et
al., 1997). When cotransfected into primary cultures, both
dnRAR
 
 
 
 and dnRXR
 
 
 
 are effective at completely blocking
activity of the RARE reporter (Fig. 2 B). Cotransfection of
the modified receptors affects Sox9 reporter activity in a
manner that is inversely proportional to their ability to
trans-activate 
 
 
 
RARE
 
3
 
-tk-Luc. Both the RAR
 
 
 
VP16 and
RXR
 
 
 
VP16 inhibit Sox9 reporter activity, whereas the dn-
RAR
 
 
 
 and dnRXR
 
 
 
 potently activate this reporter (Fig. 2,
C and D). Interestingly, the activation induced by cotrans-
fection with dnRAR
 
 
 
 is more dramatic than that elicited
by any other factor studied to date, including those exam-
ined by our laboratory and those reported previously. Sim-
ilar to the results using receptor agonists and antagonists,
Figure 1. Inhibition of RAR activity 
enhances Sox9 activity and expression. 
Activation of the retinoid receptors in 
primary limb mesenchymal cultures 
with either at-RA or the RAR -specific 
agonist AGN193836 (836) attenuates 
activity of the pGL3(4X48) Sox9 reporter 
(A); however, at-RA appears to be a 
more effective inhibitor. In contrast, 
inhibition of RAR activity by the RAR -
specific antagonist, AGN194301 (301), 
or with the RAR pan-antagonist, 
AGN194310 (310), enhances reporter 
activity with 310 being more potent than 
301. The effects of these compounds on 
activity of pGL3(4X48) are inversely 
proportional to their ability to activate a 
luciferase reporter containing an RA 
response element (pW1- RARE3-Luc) 
(B). The concentration-dependent effects 
of each compound on Sox9 reporter 
activity also correspond with the ability 
of each compound to enhance or inhibit 
cartilage formation in vitro as indicated 
by alcian blue staining (C). In response 
to AGN194301, there is an increase in 
Sox9 mRNA as early as day 2, but this 
increase appears to be transient (D). Bar, 1.5 mm. ANOVAs (A and B), P   .0001; Bonferroni post-tests indicate significant differences in 
Sox9 reporter activity at concentrations   5   10
 9 M for 310, 1   10
 7 M for 301, 5   10
 8 M for 836, and 5   10
 9 M for at-RA. Significant 
changes in activity of the RARE reporter are induced by concentrations   5   10
 9 for 310, 1   10
 7 M for 301, 5   10
 9 M for at-RA, and 
5   10
 9 M for 836, with all P values at least   0.05. 
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these studies demonstrate a strong influence of retinoid re-
ceptor activity on chondrogenesis.
 
Chondrogenic response to RAR inhibition requires 48 
bp enhancer elements within 
 
Col2a1
 
 and is specific to 
chondrogenic cells
 
To closely examine the contribution of RAR inhibition to
Sox9 activity, reporters with varying sensitivities to Sox9
were used to follow their response to the dnRAR
 
 
 
. Of four
reporters analyzed, 4X48-p89 and pGL3(4X48), which
demonstrate the greatest sensitivity to Sox9 (Fig. 3 A), also
exhibit the greatest response to dnRAR
 
 
 
 (Fig. 3 B). In con-
trast, pGL3(
 
 
 
89 6), a reporter containing only the mini-
mal Col2a1 promoter with no 48 bp Sox9 binding sites, ex-
hibits no activity in response to Sox9 and is unaffected by
the dnRAR  (Fig. 3). A reporter containing two tandem re-
peats of a larger intron-1 segment of Col2a1 (including Sox9
binding sites) along with a promoter fragment is only mildly
sensitive to Sox9 and is activated to a much lesser extent by
dnRAR  compared with the 4X48-containing reporters.
These results demonstrate a direct relationship between in-
hibition of RAR signaling and Sox9 activity.
Despite the induction of Sox9 reporter activity elicited by
dnRAR  in other cells with chondrogenic capacity, such as
dedifferentiated rat articular chondrocytes and C5.18 chon-
droprogenitor cells, activity of Sox9 reporter activity is not
noticeably affected in COS P7 cells (Fig. 4). Given that
COS P7 cells are nonchondrogenic, these results suggest
that the Sox9 reporter induction caused by RAR inhibition
may be restricted to cells with chondrogenic capacity.
Chondrogenesis requires histone deacetylase-mediated 
gene repression
Transcriptional regulation by the retinoid receptors de-
pends for the most part on ligand availability. In the
absence of ligand, RAR/RXR heterodimers bind to and re-
press the transcription of various target genes. Receptor-
mediated repression is due to association with nuclear
complexes containing corepressors (nuclear receptor core-
pressor [N-CoR] and SMRT) and histone deacetylases
(HDACs) (Nagy et al., 1997). Trichostatin A (TSA) is a
Streptomyces metabolite that specifically inhibits histone
deacetylases leading to hyperacetylation of histones and
other proteins (Finnin et al., 1999). To date, TSA has been
shown to act as a potent inducer of differentiation in many
cell types, some of which are also induced to differentiate
by treatment with RA. Interestingly, chondroprogenitors,
which in contrast to most cell types do not differentiate in
response to RA, also respond uniquely to TSA as indicated
Figure 2. Sox9 transactivation of Col2a1 is inversely associated 
with RAR activity. To further study the influence of retinoid receptor 
activity on chondrogenesis, constructs containing constitutively 
active receptors (RAR VP16 and RXR VP16) or dominant negative 
versions of the receptors (dnRAR  and dnRXR ) were used. These 
constructs substantially alter the activity of the pW1- RARE3-Luc 
reporter (A and B). RAR VP16 and RXR VP16, which enhance 
activity of the RARE reporter (A), attenuate activity of the 
pGL3(4X48) reporter (C). In contrast, the dnRAR  and dnRXR , 
which suppress RARE reporter activity (B) substantially activate 
pGL3(4X48), albeit the dnRAR  has a more dramatic effect (D). 
ANOVAs (A–D), P   .0001; Bonferroni post-tests (A–D), *P   .001.
Figure 3. Sox9 binding sites are essential for dnRAR -induced 
reporter activity. To examine the contribution of Sox9 to the effects 
of RAR inhibition, reporters with varying sensitivities to Sox9 were 
used to follow their response to the dnRAR . All reporter constructs 
were cotransfected with pcDNA3-hSox9 (A) or with dnRAR  (B). Of 
four reporters analyzed, 4X48-p89 and pGL3(4X48) are most sensitive 
to Sox9 (A) and also exhibit the greatest response to dnRAR  (B). In 
contrast, pGL3( 89 6), containing only the minimal Col2a1 
promoter with no Sox9 binding sites, exhibits no activity in response 
to Sox9 (A) and is unaffected by the dnRAR  (B). A reporter 
(pW1-Col2-Luc) containing two tandem repeats of a larger intron-1 
segment of Col2a1 (including Sox9 binding sites) along with a 
promoter fragment is only mildly sensitive to Sox9 (A) and is 
activated to a much weaker extent by dnRAR  (B) compared with 
the 4X48-containing reporters. All reporter inductions by hSox9 or 
dnRAR  were normalized to basal levels of respective reporters. 
ANOVAs (A and B), P   .0001; Bonferroni post-tests, *P   .001.RAR-mediated gene repression in chondrogenesis | Weston et al. 43
by both a dose-dependent decrease in Sox9 reporter activ-
ity (Fig. 5 A) and in cartilage nodule formation (Fig. 5 C)
in response to a TSA-induced increase in RARE reporter
activity (Fig. 5 B). TSA also attenuates the 310-induced in-
crease in Sox9 reporter activity and nodule formation (Fig.
5, A and C). The inhibitory effects of TSA on chondrogen-
esis are achieved at relatively low concentrations of TSA,
since higher concentrations have been used to induce dif-
ferentiation of many cell types including NIH3T3 cells
and acute promyelocytic leukemia blasts (Sugita et al.,
1992; Ferrara et al., 2001). Moreover, the well-character-
ized ability of TSA to inhibit IL-2 gene expression was
found to have an IC50 of 73 nM (Koyama et al., 2000),
which is greater than the highest concentration (10 nM)
used here. Thus, these results demonstrate an important
requirement for HDAC-mediated gene repression in chon-
droblast differentiation.
To further examine the importance of nuclear corepres-
sors in chondroblast differentiation, we examined the abil-
ity of a dominant negative version of N-CoR, pCMX-G/
N-CoR(2174–2453), to modulate Sox9 reporter activity.
This construct lacks the HDAC interaction domain and
contains the nuclear hormone receptor interaction domain
of N-CoR, a region similar to that of SMRT, which was
shown recently to disrupt nuclear corepressor function
(Koide et al., 2001). Consistent with these activities, the
pCMX-G/N-CoR(2174–2453) inhibited the ability of the
antagonists and the dnRAR to decrease RARE reporter
activity (unpublished data). Expression of pCMX-G/N-
CoR(2174–2453) alone led to an  50% decrease in basal
Sox9 reporter activity. Moreover, coexpression of pCMX-
G/N-CoR(2174–2453) completely inhibited the stimula-
tory effects of 301 and 310 and repressed the effect of the
dnRAR on the Sox9 reporter (Fig. 5 D). These results sug-
gest that active repression by RARs is required for chon-
droblast differentiation and that this repression requires
deacetylase activity.
RAR inhibition activates the p38 MAPK and 
PKA pathways
To elucidate the mechanism whereby a loss in RAR activity
leads to enhanced Sox9 activity, pathway profiling vectors
were used to uncover signal transduction pathways that act
downstream of retinoid signaling. Various reporters contain-
ing reiterated enhancer sequences were transiently cotrans-
fected into primary cultures with a dnRAR . Cotransfection
with the dnRAR  was used as it is a potent constitutive re-
pressor that consistently induces high Sox9 activity in pri-
mary cells. The luciferase-based reporters used contained re-
sponse elements for activating protein-1 (pAP-1-TA-Luc),
cAMP (pCRE-TA-Luc), nuclear factor of  B cells (pNF B-
TA-Luc), nuclear factor of activated T cells (pNFAT-TA-
luc), serum, (pSRE-TA-Luc), glucocorticoids (pGRE-TA-
Luc), and interferons (pISRE-TA-Luc). Each vector con-
Figure 4. Induction of Sox9 activity by dnRAR  is observed in 
other chondrogenic cells. The induction of Sox9 reporter activity by 
dnRAR  in different cells compared with vector-transfected ( ) 
controls is shown. The effect of dnRAR  on Sox9 reporter activity is 
consistent in chondrogenic cells, since considerable increases in 
pGL3(4X48) are induced not only in limb mesenchymal cells but 
also in rat articular chondrocytes and in C5.18 cells, which both 
have chondrogenic capacity. In contrast, no noticeable change in 
reporter activity is induced in the nonchondrogenic COS P7 cells. 
Student’s t tests, *P   .001.
Figure 5. Histone deacetylase-mediated gene repression is 
required for chondrogenesis. The effects of TSA on Sox9 reporter 
activity in the presence or absence of AGN194310 (A) and on pW1-
 RARE3tkLuc (B) were analyzed. TSA attenuated Sox9 reporter 
activity in a concentration-dependent manner and inhibited the 
effects of AGN194301 (A). In contrast, TSA enhanced activity of the 
pW1- RARE3tkLuc reporter in a concentration-dependent manner 
(B). The inhibition in Sox9 reporter activity correlates with the 
decrease in the number of cartilage nodules forming in response to 
TSA as seen in day 4 alcian blue-stained cultures (C). The increases 
in Sox9 reporter activity induced by cotransfection with dnRAR  or 
by treatment with AGN194301 or AGN194310 are attenuated by 
coexpression of pCMX-GAL4/N-CoR (D). Bar, 1.5 mm. ANOVAs 
(A and B), P   0.0001 for all cases; Bonferroni post-tests (A and B), 
*P   .01, **P   .001, and ***P   .0001, all versus respective 
control cultures; Student’s t tests (D), **P   .001 and ***P   .0001.44 The Journal of Cell Biology | Volume 158, Number 1, 2002
tained the reiterated response elements upstream of a TATA
box and the luciferase gene. Interestingly, when cotransfected
with a dnRAR   the only reporters appreciably affected
(greater than twofold increases) were pCRE-TA-Luc and
pAP-1-TA-Luc. Cotransfection with dnRAR  enhanced ac-
tivity of these reporters by greater than fourfold (Fig. 6, A
and B), indicating that RAR inhibition may result in activa-
tion of pathways upstream of CRE and AP-1 responses.
The PKA pathway is a predominant pathway through
which genes containing a cAMP-response element (CRE)
are activated. When activated through various stimuli, PKA
phosphorylates CRE binding protein (CREB), which binds
to and activates genes containing cAMP response elements.
Accordingly, cotransfection of pCMV-PKA dramatically en-
hances activation of pCRE-TA-Luc (unpublished data).
Given that a pCRE-TA-Luc is activated in cells transfected
with a dnRAR , we tested the ability of this modified recep-
tor to induce activation of CREB. A chimeric trans-activator
protein containing CREB fused to the DNA binding do-
main of the yeast transcriptional activator GAL4 (pFA-
CREB) was transiently transfected into cells with a luciferase
reporter containing a reiterated GAL4 DNA binding ele-
ment. Thus, by monitoring the activity of the pG5-Luc re-
porter the activation of FA-CREB was indirectly followed.
Cotransfection of pCMV-PKA into the primary cultures
induced an  40-fold increase in pG5-Luc (Fig. 6 C). Co-
transfection with dnRAR  enhanced FA-CREB-induced
transactivation of pG5-Luc by approximately sixfold.
In addition to the PKA pathway, we investigated poten-
tial mechanisms that may underlie the activation of AP-1
by dnRAR . Activating protein-1 collectively refers to
dimeric transcription factors composed of Jun, Fos, or acti-
vating transcription factor (ATF) subunits. Surprisingly, a
dominant negative version of Fos (A-Fos), which substan-
tially diminishes pAP-1-TA-Luc reporter activity, was
found to have no noticeable effect on activity of the Sox9
reporter (unpublished), suggesting that the induction of
pAP-1-TA-Luc by dnRAR  does not involve activation of
Jun/Fos dimers. Moreover, constitutively active versions
of kinases within the MAPK pathways were tested for their
ability to modulate Sox9 transactivation. Of the kinases
known to be upstream of AP-1 activation, only a constitu-
tively active version of MKK6 (MKK6E) consistently led to
increased Sox9 reporter activity. The predominant targets
of MKK6 appear to be the p38 mitogen-activated protein
kinase (MAPK) isoforms. When phosphorylated, p38 phos-
phorylates and activates several targets including the AP-1
component ATF2. As a positive control, MKK6E was
cotransfected into cells and found to induce activity of
pAP-1-TA-Luc (unpublished data). Given that ATF2 has
been shown to bind to AP-1 response elements, we used the
pG5-Luc reporter to measure the activity of FA-ATF2, a
chimeric of ATF2 and the DNA binding domain of GAL4.
Cotransfection of dnRAR  induced an increase in FA-
Figure 6. The p38 MAPK pathway and the PKA pathway are 
activated in response to RAR inhibition. Reporters containing a 
cAMP response element (pCRE-TA-Luc) or activator protein-1 
response element (pAP-1-TA-Luc) are both activated in response to 
cotransfection with dnRAR  (A and B). Cotransfection with dnRAR  
also induces transactivation of a GAL4 reporter (pG5-Luc) by the 
transcription factors ATF2 and CREB, both of which are fused to the 
DNA binding domain of GAL4 (FA-ATF2 and FA-CREB) (C and D). 
The ability of PKAc and MKK6E to activate FA-CREB and FA-ATF2, 
respectively, was tested for positive control purposes. Student’s t 
tests (A and B), *P   .0005; ANOVAs (C and D), P   .0001; Bonferroni 
post-tests (C and D), 
#P   .0001, **P   .001, and ***P   .01.
Figure 7. Inhibition of p38 and PKA prevents 
chondrogenesis. In the presence of 5 or 10  M 
SB202190, there is a decrease in Sox9 reporter activity 
compared with untreated controls (A). SB202190 also 
attenuates the chondrogenic response to AGN194301 
and the dnRAR  (A). This inhibition is reflected by a 
lack of cartilage formation in vitro, since almost no 
cartilage nodules form in response to 10  M SB202190 
(D) in contrast to the presence of numerous nodules in 
untreated control cultures (C). Similar to SB202190, the 
PKA inhibitor H89 reduces Sox9 reporter activity both in 
the presence or absence of AGN194301 or dnRAR  (B). 
In H89-treated cultures (10  M) (F), fewer nodules are 
detected compared with untreated cultures (E); these 
nodules are much smaller and stain only weakly with 
alcian blue. Bar, 1.5 mm. ANOVAs (A and B), 
P   .0001; Bonferroni post-tests (A and B), *P   .05, 
**P   .01, ***P   .001, and 
#P   .005, all versus 
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ATF2 activation of pG5-Luc that was almost as robust as
the induction by MKK6E (Fig. 6 D).
Further support for the role of p38 MAPK and PKA in
chondroblast differentiation comes from the reduction in
Sox9 reporter activity caused by the p38 MAPK inhibitor
SB202190 and the PKA inhibitor H89 (Fig. 7, A and B).
These inhibitors also attenuated the induction of Sox9 re-
porter activity by dnRAR  and by 301 (Fig. 7, A and B).
Consistent with this, the inhibitors at 10  M inhibited the
formation of cartilage nodules in untreated (Fig. 7, D and F)
and 301-treated cultures (unpublished data) compared with
untreated cultures (Fig. 7, C and E).
Activation of ATF2 and CREB induces Sox9 
transactivation response
The studies described above suggest that the suppression of
RAR activity leads to activation of the p38 MAPK and PKA
signaling pathways. Phosphorylation of ATF2 and CREB is
reflective of activation of p38 MAPK and PKA signaling
pathways, respectively. To further investigate a possible role
for these signaling pathways in the activation of Sox9, fac-
tors involved in these pathways were transiently transfected
into the mesenchymal cells along with the Sox9 reporter.
Transient transfection of a constitutively active version of
MKK6 (MKK6E) induces an approximate threefold activa-
tion of FA-ATF2 (Fig. 8 A). When transfected along with
p38  or p38 , MKK6E is able to induce FA-ATF2 activity
by  13- and 14-fold, respectively, and even more so with
the two isoforms together. However, p38  and p38  alone
or in combination have no noticeable effect on Sox9 activ-
ity. The ability of each expression plasmid to induce activa-
tion of FA-ATF2 is directly proportional to their influence
on Sox9 reporter activity (Fig. 8 B), with a  4.5-fold activa-
tion by cotransfection with MKK6E along with p38  and
p38 . Similarly, Sox9 is activated by the catalytic subunit of
PKA, which potently enhances FA-CREB activity. How-
ever, the induction of Sox9 activity by PKA is relatively mild
given the level of FA-CREB activation elicited by PKA.
These results demonstrate the relevance of activation of the
p38 and PKA pathways by dnRAR , since each pathway has
the potential to induce Sox9 transactivation of Col2a1.
Sox9 DNA binding and hence its transcriptional activity
has been shown to be induced by PKA-mediated phosphory-
lation of serines 64 and 181 (Huang et al., 2000). Specifi-
cally, PKA phosphorylation of serine 181 in Sox9 was found
to occur in chondrocytes of the prehypertrophic zone in re-
sponse to parathyroid hormone-related peptide (Huang et
al., 2000, 2001). To determine if the same phosphorylation
event occurs here in response to RAR antagonism, we com-
pared the ability of dnRAR  to induce Sox9 reporter activ-
ity in the presence of a cotransfected vector containing
wtSox9 versus a mutant Sox9 in which serine 181 was re-
placed with alanine (Sox9-181A). In the absence of exoge-
nous Sox9, Sox9 reporter activity is increased  4.5 fold by
activation of the PKA pathway using pCPT-cAMP (500
 M) in comparison to an  9-fold increase by coexpression
of dnRAR . Cotransfection with wt Sox9 or Sox9-181A in-
creased reporter activity  100 fold, and this was further in-
creased, albeit slightly in each case ( 1.5 fold), by the addi-
tion of pCPT-cAMP or by coexpression of PKAc or a
dnRAR  and decreased by the addition of H89 (Fig. 9 A;
unpublished data). There is no significant difference in the
activity of Sox9 versus Sox9-181A, suggesting that phos-
phorylation of serine 181 is not required for Sox9 activity
during chondroblast differentiation. As mentioned, immu-
nolocalization studies detected Ser181-phosphorylated Sox9
in prehypertrophic chondrocytes. However, the cells used here
are chondroprogenitors, and thus, Sox9 activity may be
Figure 8. Activation of ATF2 or CREB induces Sox9 transactivation 
response. The effects of different components of the p38 signaling 
cascade on ATF2 induction were analyzed. Transient transfection 
with MKK6E induces ATF2 activity greater than twofold; however, 
transient expression of p38  or p38  either alone or in combination 
has no appreciable effect on FA-ATF2 activity (A). However, when 
cotransfected with MKK6E, p38  or p38  can enhance FA-ATF2 
activity considerably, and when both isoforms are transfected 
together along with MKK6E there is an even greater induction of 
FA-ATF2 (A). The effects of MKK6E, p38 , and p38  on Sox9 
reporter activity corresponds with their ability to activate FA-ATF2 
(B). MKK6E induces an almost 2.5-fold increase in activity of 
pGL3(4X48), whereas p38  and p38  alone have no noticeable
effect. When cotransfected with MKK6E, p38  and p38  each 
enhance Sox9 reporter only slightly, but when transfected together 
along with MKK6E the increase in Sox9 transactivation is greater 
than fourfold (B). PKAc induces FA-CREB activity by  30-fold (C) 
but only enhances Sox9 reporter activity slightly (by  2-fold) (D). 
ANOVAs (A and B), P   .0001; Bonferroni post-tests, *P   .001 (A) 
and *P   .001 (B); Student’s t test, **P   .0005 (C), *P   .001 (D).46 The Journal of Cell Biology | Volume 158, Number 1, 2002
regulated through distinct posttranslational modifications
within each cell type. To ensure that the mutant Sox9 func-
tions in a manner consistent with that reported previously
(Huang et al., 2000), wtSox9 and Sox9-181A were trans-
fected into COS P7 cells in the presence or absence of an ex-
pression vector for the catalytic subunit of PKA. COS P7
cells were originally used to identify Ser181 as the PKA
phosphorylation site, and as expected the ability of PKAc to
activate Sox9 in these cells is almost completely blocked by
the Ser181 mutation (Fig. 9 B). Thus, similar to earlier re-
ports Ser181 of Sox9 appears to be required for increased ac-
tivation of Sox9 by PKA in these cells, but this is clearly not
the case in the limb mesenchymal cells used in this study.
To determine if modulation of PKA activity affects the ex-
pression of Sox9 and Col2a1 transcripts, real-time quantita-
tive PCR was used to measure their relative expression levels
in comparison to rRNA. Sox9 and Col2a1 expression were in-
creased by more than twofold in response to a 2-d treatment
with pCPT-cAMP (500  M) and decreased by more than
twofold in response to H89 (10  M) (Fig. 9 C). A similar in-
crease in Col2a1 expression by activation of PKA in limb
mesenchymal cultures has been reported previously (Kosher
et al., 1986). Therefore, our results suggest that PKA regu-
lates Sox9 activity during chondroblast differentiation by in-
fluencing Sox9 expression levels and not through phosphory-
lation of Ser181. However, a posttranslational role for PKA
modulation of Sox9 cannot be entirely excluded, since
Figure 9. Regulation of Sox9 expression and transcriptional 
activity by PKA. Sox9 expression and activity were measured in 
response to manipulation of the PKA signaling pathway. In the 
absence of exogenous Sox9, addition of pCPT-cAMP (500  M) or 
cotransfection with dnRAR  increases Sox9 reporter activity, 
whereas H89 (10  M) represses reporter activity in primary limb 
mesenchymal cells (A). In the presence of cotransfected Sox9, 
reporter activity is elevated  100-fold, and the addition of pCPT-
cAMP or cotransfection with dnRAR  only has a small stimulatory 
effect ( 1.5 fold), whereas the addition of H89 slightly decreases 
reporter activity. The response of the mutant Sox9-181A is similar to 
wild-type Sox9 (A). To demonstrate that the mutation functioned as 
expected, COS P7 cells were transfected with wild-type Sox9 or the 
mutant Sox9 in the presence or absence of PKA (B). The presence of 
PKA leads to a  1.5-fold induction in reporter activity, whereas the 
mutant Sox9 exhibits little increase with cotransfected PKA. 
Modulation of PKA signaling influences Sox9 and Col2a1 expression 
in primary limb mesenchymal cells (C). Real-time quantitative PCR 
was used to demonstrate that activation of PKA leads to an increase 
in Sox9 and Col2al mRNA abundance, whereas treatment with H89 
suppresses their expression. ANOVAs (A–C), P   .0001; Bonferroni 
post-tests (A–C), *P   .05, **P   .01, and ***P   .001, all versus 
respective nontreated controls.
Figure 10. Activation of ATF2 or CREB can rescue the effects of 
RAR VP16. The ability of ATF2 and CREB to reverse the effects of 
RAR VP16 on Sox9 reporter activity was analyzed. MKK6E can 
partially prevent the inhibitory response of RAR VP16 whereas 
p38  and p38  alone or in combination had little if any effect (A). 
Cotransfection with MKK6E and p38  or p38  was able to partially 
restore Sox9 activity, whereas cotransfection of MKK6E with both 
p38  and p38  can completely restore the effects of RAR VP16 (A). 
Activation of PKA by transient transfection with PKAc was also able 
to restore Sox9 reporter activity to basal levels in RAR VP16-
transfected cultures. ANOVA (A and B), P   .0001; Bonferroni 
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cotransfected Sox9s do exhibit slightly increased activity in
the presence of cAMP or cotransfected PKA.
The influence of p38 MAPK and PKA signaling pathways
on chondrogenesis is best demonstrated by their ability to
rescue the decrease in Sox9 activity induced by RAR VP16
(Fig. 10). Although Sox9 activity is only partially restored by
cotransfection with RAR VP16 and MKK6E, transfection
of each isoform in combination with MKK6E results in lev-
els of Sox9 activity that are almost as high as those obtained
in the absence of RAR VP16. Not surprisingly, MKK6E
cotransfected with both isoforms of p38 (which causes the
most pronounced activation of ATF2) results in a complete
rescue of Sox9 activity (Fig. 10 A). Similarly, PKAc can al-
most completely rescue the effects of RAR VP16 (Fig. 10
B). These results are not due to modulation of RAR VP16,
since neither MKK6E or PKAc inhibited RAR VP16 in-
duction of an RARE reporter (unpublished data).
Discussion
The precise timing of differentiation during development
is critical for the establishment of a properly patterned
embryo. Previously, we identified an important role for
RAR activity in the timing of chondroblast differentiation
(Weston et al., 2000), prompting us to investigate the mech-
anism underlying retinoid receptor regulation of the pre-
chondroblast-to-chondroblast transition. Of the three Sox
genes identified to date as chondrogenic regulators, Sox9 has
emerged as a central player in regulating the initial stages of
the chondrogenic process. Moreover, to reproduce the pat-
tern of Col2a1 expression in the cartilage elements with a re-
porter gene only a small (48 bp) enhancer element from the
first intron of Col2a1 containing Sox9 binding sites is re-
quired. For these reasons, Sox9 is commonly referred to as a
“master regulator” of chondrogenesis, and as such, analysis
of Sox9 expression and activity was an obvious starting point
for identifying factors downstream of RAR activity that may
mediate the effects of RAR activation or inhibition.
Association between retinoid receptor activity and 
Sox9 transactivation
Using soluble compounds in combination with expression
plasmids, we have demonstrated a surprisingly tight correla-
tion between retinoid receptor activity and Sox9 transactiva-
tion of Col2a1. The extent of RAR inhibition was found to
be inversely proportional to the level of Sox9 induction.
Moreover, manipulations affecting all three RARs were more
influential than those affecting only the RAR  subtype, indi-
cating the importance of at least two RAR subtypes in chon-
drogenesis. Of particular interest was the dramatic induction
of Sox9 activity upon cotransfection with dnRAR . To date,
no single factor has been shown to induce Sox9 to a similar
extent, including numerous factors known to potently stim-
ulate chondrogenesis such as BMPs-2 and -4 either in solu-
ble form or after cotransfection of expression plasmids con-
taining activated BMP receptors (unpublished data). The
ability of the dnRAR  to stimulate Sox9 activity to a much
greater extent than 301 or 310 is likely due to the constitu-
tive repressive activity of the truncated receptor. Consistent
with this, the dnRAR  has been shown previously to exhibit
enhanced association with nuclear corepressors (Wong and
Privalsky, 1998). Interestingly, the ability of the dnRXR to
significantly enhance Sox9 activity also suggests that the ab-
sence of the RXR AF-2 domain may facilitate formation of
an RAR/dnRXR–nuclear corepressor complex.
The more pronounced effects of AGN 194310 and at-RA
compared with the more specific compounds, AGN 194301
and AGN 193836, respectively, implicates the involvement
of at least two receptor subtypes in regulating chondroblast
differentiation. These results are further supported by the ef-
fects of the dnRAR , which broadly inhibits RAR-mediated
signaling (Damm et al., 1993). Together, these studies sug-
gest that a loss of the ligand-induced activity of multiple
RARs can initiate chondroblast differentiation. Accordingly,
these findings explain the failure of cells expressing a weak
constitutively active RAR in transgenic mice to differentiate
into chondroblasts and contribute to cartilage nodules. Con-
tinued RAR activity would result in a reduction of Sox9 ex-
pression and/or activity, thereby preventing chondroblast
differentiation, similar to that observed in Sox9-null cells.
Interestingly, addition of RA was shown recently to cause a
downregulation of Sox9 in chondrocytes (Sekiya et al.,
2001). However, it is unclear from this study whether this
reduction is due to a loss of the chondrocyte phenotype or
by a transition to hypertrophic chondrocytes, both of which
are induced by RA and are associated with a reduction in
Sox9 expression (Horton et al., 1987; Koyama et al., 1999).
Importance of RAR-mediated repression in 
chondroblast differentiation
Our results clearly demonstrate a critical role for retinoid re-
ceptors in chondrogenesis. Surprisingly, homozygous mu-
tant mice lacking individual RARs develop essentially nor-
mal skeletons with the exception of RAR  knockout mice in
which homeotic transformations of the cervical vertebra and
occipital region of the skull are observed along with other
minor irregularities such as fusion of the first and second
ribs (Li et al., 1993; Lohnes et al., 1993; Lufkin et al., 1993;
Mendelsohn et al., 1994; Luo et al., 1995; Kastner et al.,
1996; Krezel et al., 1996; Ghyselinck et al., 1997; Iulianella
and Lohnes, 1997). The minor phenotypes observed in sin-
gle RAR KOs have, for the most part, been attributed to the
existence of functional redundancy between members of the
RAR family. Indeed, embryos in which multiple RARs are
deleted exhibit more extensive skeletal defects (Lohnes et al.,
1994). However, these effects are less severe than expected
based on the dramatic teratogenic effects of RA and the ef-
fects observed in mice deficient in enzymes involved in RA
synthesis or degradation (Niederreither et al., 1999; Abu-
Abed et al., 2001; Sakai et al., 2001).
The discrepancy between our results and the RAR knock-
out studies may be the result of distinct approaches used in
manipulating receptor function. In the present study, we
used complimentary approaches to examine the role of RAR
repression in skeletal progenitor differentiation. Overexpres-
sion of a dnRAR  or the addition of soluble RAR antago-
nists effectively abolishes transcriptional activation while at
the same time maintaining or enhancing active repression.
However, in the knockout mice the receptors are entirely ab-
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pressors. Consequently, genes that would normally be re-
pressed by the receptors in the absence of ligand may exhibit
increased expression.
The important role, demonstrated herein, for RAR-medi-
ated repression is consistent with the recently described re-
quirement for RAR-mediated repression in Xenopus head
formation (Koide et al., 2001). Specifically, activation of the
retinoid-signaling pathway was found to adversely affect the
development of anterior structures, which could be mim-
icked by overexpression of a dominant negative SMRT lack-
ing its repression domains. In contrast, repression of RAR-
mediated signaling by RAR antagonists was shown to promote
the expression of anterior neural markers and to enhance the
formation of anterior head structures.
Direct evidence for the importance of unliganded nuclear
hormone receptors also comes from studies in which the
thyroid hormone receptor (TR) of mice was mutated to
abolish the ligand binding function of the receptor (Hash-
imoto et al., 2001). Despite TR knock-out animals having
completely normal structure and function of the central ner-
vous system, mice containing the mutated TR exhibit severe
neurological development and dysfunction (Hashimoto et
al., 2001). These latter effects are more consistent with the
severe CNS dysfunction exhibited in cases of congenital hy-
pothyroidism and thyroid hormone resistance syndrome.
Collectively, these results combined with our findings,
which demonstrate a requirement for RAR-mediated repres-
sion during skeletal development, form an emerging theme
whereby retinoid receptors have an important biological role
during development in the absence of ligand.
The mechanisms of retinoid regulation of 
chondroblast differentiation
In addition to establishing a critical role for RAR-mediated
repression in skeletal development, our findings provide a
framework to describe the molecular regulation of chondro-
blast differentiation. Previously, we provided evidence to sug-
gest that BMP signaling operates upstream of the retinoid
signaling pathway in chondrogenesis (Weston et al., 2000).
Here, we show that repression of RAR-mediated signaling re-
sults in the activation of p38 MAPK and PKA signaling path-
ways and that the effects of RAR antagonism on chondrogen-
esis can be blocked by inhibition of p38 MAPK and PKA
activity. P38 MAPK and PKA have both been implicated
previously in cartilage formation (Kosher et al., 1986; Lee
and Chuong, 1997; Nakamura et al., 1999; Yoon et al.,
2000). Specifically, we have found that inhibition of MAPK
p38  and/or   prevents cartilage formation and attenuates
Sox9 reporter activity. Conversely, activation of the p38  or
p38  pathways is sufficient to promote Sox9 activity. More-
over, activation of p38 /  or PKA signaling are the only
means identified to date, with the exception of expression of
Sox9, that rescue the negative effects of activation of the
RAR-signaling pathway on chondrogenesis. Together, these
results suggest that activation of the p38 MAPK and PKA
pathways upon RAR-mediated gene repression is necessary
for acquisition of the chondroblast phenotype.
The ability of gene repression by the RARs to induce chon-
droblast differentiation suggests that retinoid signaling di-
rectly regulates the expression of a gene(s) whose function is
to inhibit chondroblast differentiation. This novel role for
gene repression in chondroblast differentiation is opposite to
that of myogenic cells in which gene repression prevents dif-
ferentiation. TSA stimulates differentiation of muscle pro-
genitors, consistent with the recently described requirement
for HDAC export from the nucleus before expression of the
myoblastic phenotype (McKinsey et al., 2000). Thus, al-
though the status of histone acetylation represents a general
mechanism underlying cell differentiation the outcome of
such modifications is cell type dependent. In this context, op-
posite roles for RAR-mediated gene repression in different
progenitors may provide a means whereby a common local
signal (RA) can differentially regulate cell differentiation. In
chondroprogenitors, this repression can clearly direct changes
in Sox9 activity; thus, identifying the genes affected directly
by RAR repression in the chondrogenic sequence will un-
doubtedly further enhance our current understanding of the
molecular networks underlying chondroblast differentiation.
Materials and methods
Expression plasmids and reporter constructs
The Sox9-responsive reporter (herein referred to as the Sox9 reporter) was
generated by subcloning a fragment containing a reiterated (4X48) Sox9
binding sequence coupled to the mouse Col2a1 minimal promoter ( 89 to
 6) into pGL3. The fragment containing the 4X48 repeat and minimal pro-
moter was isolated as a BamHI/HindIII fragment from the original 4X48-
p89Luc reporter plasmid described previously (Lefebvre et al., 1997) and
was subcloned into the BglII and HindIII sites of pGL3-basic (Promega) to
generate pGL3(4X48). The reporter pW1-Col2-Luc was generated from the
original p309i(182X2) geoCol2a1 (Zhou et al., 1995) by subcloning the
regulatory region (consisting of a 309-bp promoter region and two tandem
repeats of a 182-bp intron-1 fragment) into pW1 (Balkan et al., 1992) as an
EcoRI/BamHI fragment. A BglII fragment containing the luciferase gene
isolated from pJD205 (de Wet et al., 1987) was subcloned into the BamHI
site of pW1-Col2 to generate pW1-Col2-Luc. The pcDNA3-hSox9 expres-
sion vector was as described (Lefebvre et al., 1997). To generate a mutated
form of hSox9, hSox9 was subcloned into pKSII (Stratagene), and serine
181 was replaced with alanine using the Quick-Change XL system (Strat-
agene) with the following overlapping primers: 5 -GCCGCGGCGGAG-
GAAGGCGGTGAAGAACGGGCAGG-3  and 5 -CCTGCCCGTTCTTCAC-
CGCCTTCCTCCGCCGCGGC-3 . After mutagenesis, the Sox9 mutant and
wt Sox9 were subcloned into pcDNA3, and the serine-alanine conversion
was confirmed by sequencing.
The dominant negative versions of RAR  and RXR  were generated as
enhanced green fluorescent protein (EGFP) fusions containing COOH-ter-
minal truncations at amino acid positions 403 and 449, respectively
(Damm et al., 1993; Feng et al., 1997). A BglII restriction endonuclease
site was incorporated into the primers to facilitate cloning and to allow for
an in-frame fusion to pEGFP-N1 (CLONTECH Laboratories, Inc.). Internal
primers used for truncation of the receptors were as follows: 5 -AGA-
TCTGGGATCTCCATCTTCAATG-3  for RAR  and 5 -CAGATCTCCGAT-
GAGCTTGAAGAAG-3  for RXR . For expression in cells, receptor–EGFP
fusion constructs were cloned into the mammalian expression plasmid
pSG5 (Stratagene). EGFP-N1 was initially subcloned into the pSG5 vector
followed by the corresponding truncated receptor to generate pSG5-
dnRAR EGFP and pSG5-dnRXR EGFP.
Constitutively active versions of RAR  and RXR  were subcloned into
pSG5HS as Hind III/SpeI fragments isolated from the constructs described
(Underhill et al., 1994). These receptors contain COOH terminal fusions to
the acidic activation domain of VP16 (Underhill et al., 1994). The constitu-
tively active version of MKK6 used here was the previously described
pcDNA3-HA-MKK6E (Han et al., 1996). Expression plasmids, pcDNA3-
p38 -Flag, and pcDNA3-p38 2-Flag were used to express p38  and
p38 2 in mesenchymal cells (Enslen et al., 1998). To activate the PKA
pathway, pCMV-PKA (CLONTECH Laboratories, Inc.), which contains the
catalytic subunit of PKA was used. To follow activation of ATF2 and CREB,
constructs containing the transactivation domain of these transcription fac-
tors fused to the DNA binding domain of GAL4 (pFA-ATF2 and pFA-CREB)
were used (Stratagene). The pFA-ATF2 and pFA-CREB plasmids were
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DNA binding element upstream of a TATA box and the luciferase gene
(Stratagene). PCMX-N-CoR and pCMX-GAL4/N-CoR (2174–2453) (re-
ferred to as pG/N-CoR[2,174–2,453] herein) consists of the DNA binding
domain of GAL4 fused to the 3  region of N-CoR encompassing amino ac-
ids 2,174–2,453 as described (Heinzel et al., 1997).
Reporter vectors from Systems 1 and 2 of CLONTECH Laboratories
Inc.’s Mercury Pathway Profiling Systems were used to identify pathways
downstream of retinoid signaling. These systems are sets of vectors that
contain distinct cis-acting enhancer elements upstream of a TATA box and
the luciferase gene.
Establishment and transient transfection of primary limb 
mesenchymal cultures
Limb mesenchymal cells were harvested from embryonic age 11.25–11.75
mouse embryos as described previously (Weston et al., 2000). The cells
were resuspended at a density of  2.5   10
7 cells/ml before transfections;
otherwise, they were resuspended at  1.5   10
7 cells/ml. For transfection
purposes, cells were mixed with a DNA/FuGene6 mixture in a 2:1 ratio.
FuGene6-DNA mixtures were prepared according to the manufacturer’s in-
structions (Roche Biomolecular). Briefly, 1  g of reporter, 1  g of expression
vector, and 0.05  g of pRLSV40 (Promega) were mixed for a total of  2  g
DNA in 100  l of media and FuGene6. Fifty microliters of the DNA mixture
was transferred into a sterile 1.5 ml Eppendorf tube followed by 100  l of
cells. Cells were gently triturated, and 10  l was used to seed each single
well of a 24-well culture dish. After 1.5 h in a humidified CO2 incubator, 1
ml of media containing compounds of interest was added to each well and
subsequently replaced 24 h after transfection. All-trans RA (at-RA; Sigma-
Aldrich), AGN193836 (Teng et al., 1996), AGN194301 (Teng et al., 1997),
and AGN194310 (Johnson et al., 1999) (Allergan Inc.) were dissolved in
95% ethanol. SB202190 and SB203580 (Calbiochem) and H89 (Sigma-
Aldrich) were dissolved in DMSO (BDH). 8-(4-chlorophenylthio)-cAMP
(pCPT-cAMP; Sigma-Aldrich) was dissolved in water just before use.
Analysis of reporter gene activity using the Dual Luciferase Assay Sys-
tem was done following the manufacturer’s instructions (Promega). Briefly,
 48 h after the transfections cells were washed once with PBS and lysed
in 100  l of Passive lysis buffer for 20 min. Firefly and renilla luciferase ac-
tivities were determined using 40  l of lysate in a 96-well plate-reading lu-
minometer (Molecular Devices). Alcian blue staining of cultures was per-
formed as described previously (Cash et al., 1997).
Cell culture and transient transfection of cell lines
COS P7 cells were maintained in DME containing 10% FBS (GIBCO-BRL)
and antibiotics. C5.18 cells, subcloned from the parental chondroblast
clone RCJ 3.1C5 (Grigoriadis et al., 1996), were maintained in  -MEM
supplemented with 15% FBS and antibiotics. Articular chondrocytes were
derived from the knee joints of 1-d-old Sprague-Dawley rats. Briefly, 1–2-
mm cartilage fragments from the femoral condyles were isolated, washed
three times in sterile PBS, and digested with 0.3% Collagenase P (Wor-
thington Biochemical Corporation) at 37 C for 4 h, adding fresh collage-
nase P after the first 30 min. After digestion, cells were filtered through a
cell strainer (70  m; Falcon) to obtain a single cell suspension. PBS/Colla-
genase was removed, cells were resuspended at  1.5   10
5 cells/ml, and
6 ml were transferred to a T-25 tissue culture flask. Upon reaching conflu-
ence, cells were transferred to a T-75 flask.
For transient transfections, the cells described were plated at 5   10
4
cells/well in 12-well tissue culture plates  24 h before transfection.
FuGene6 transfection reagent was used according to manufacturer’s in-
structions (Roche Biomolecular). Each well of cells was transfected with a
FuGene-DNA mixture containing a total of 0.5  g DNA comprised of 0.3
 g of reporter, 0.2  g of expression vector, and 0.05  g of pRLSV40. Me-
dia was changed  24 h after transfection, and luciferase assays were per-
formed  48 h after transfection. Luciferase assays were done as described
above with the exception of using 200  l/well of Passive lysis buffer
(Promega) to obtain cell extracts.
Northern blot analysis and real-time quantitative PCR
Northern blots were performed using total RNA from limb mesenchymal
cultures as described previously (Weston et al., 2000). Briefly, total RNA
was extracted from cells cultured for 2, 4, 6, or 8 d. Cells were treated with
media alone or with AGN194301. Synthesis of the Col2a1 cDNA fragment
used was as described previously (Weston et al., 2000). The Sox9 cDNA
probe was made using an EST clone (GenBank/EMBL/DDBJ under acces-
sion no. AI594348 [Research Genetics]). The Sox9 fragment was released
from pT7T3 using EcoRI and NotI.
To monitor changes in transcript levels of Sox9 and Col2a1, quantitative
real-time PCR was performed using the 7900HT Sequence Detection Sys-
tem (Applied Biosystems). Primers and TaqMan–minor groove binding
probes were designed using PrimerDesigner 2.0 (Applied Biosystems).
The following primer/probe sets were used for detection of Col2a1: for-
ward primer, 5 -GGCTCCCAACACCGCTAAC, reverse primer, 5 -GATGT-
TCTGGGAGCCCTCAGT, and probe 6FAM-5 -CAGATGACTTTCCTC-
CGTC-MGBNFQ. Sox9 transcripts were detected using the forward primer,
5 -CATCACCCGCTCGCAATAC, reverse primer, 5 -CCGGCTGCGTGACT-
GTAGTA, and probe, 6FAM-5 -ACCATCAGAACTCCGGCT-MGBNFQ.
Primer and probe concentrations were optimized according to the manu-
facturer’s instructions. Total RNA was isolated from primary cultures as de-
scribed above and treated with amplification-grade DNase I (Invitrogen).
Quantification was performed using 4 ng of total RNA, and the expression
of Sox9 or Col2a1 relative to endogenous rRNA was determined using Taq-
Man Ribosomal Control Reagents (Applied Biosystems) and the compara-
tive CT method as described in User Bulletin no. 2 (Applied Biosystems).
Statistical analysis
All luciferase assays were performed a minimum of three times using sepa-
rate preparations of primary cells each time. Each transfection or treatment
was performed in quadruplicate for all experiments, with the exception of
the COS cell transfections which were performed in triplicate. Real-time
PCR analysis was performed using RNA from two separate preparations
with treatments done in triplicate for each preparation. All luciferase re-
porter and expression data was analyzed by analysis of variance (ANOVA)
followed by a Bonferroni post-test for multiple comparisons using Graph-
Pad Prism, version 2.0 (GraphPad Software Inc., San Diego, CA). One rep-
resentative experiment is shown for all luciferase and expression results.
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